

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 25117

Title: Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

Reviewer's code: 03383645

Reviewer's country: Egypt

Science editor: Xue-Mei Gong

Date sent for review: 2016-02-24 11:32

Date reviewed: 2016-03-03 07:37

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

The study Boceprevir or Telaprevir in HCV chronic infection: the Italian real life experience describes the role of antiviral therapy for HCV chronic infection in the everyday practice. The topic is important and of interest for the reader of the journal. However, some points deserve mention. Although the study is a multicenter one and conducted on a large sample size, the data presented are quite poor giving the impression that the paper seem to be a short communication or just a reporting. Authors must have produced some correlations with test of significance for adverse events and treatment discontinuation and patient demographics. The discussion section is also quite poor, the authors should compare their findings with relevant national work and worldwide. A paragraph on recommendations and another on study limitations should be added.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 25117

Title: Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

Reviewer's code: 02941540

Reviewer's country: Ireland

Science editor: Xue-Mei Gong

Date sent for review: 2016-02-24 11:32

Date reviewed: 2016-03-11 21:32

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This topic of study is very topical and important for this field. The current study has a board range of expert centres that wish to report their experience in the context of treatment as put, the real life experience. Indeed, it is important to report such finding in this area and large scale efforts in this regards will no doubt be central in the formation of useful procedure in the future. The studies topic is very useful. Of course the manuscript would be need to checked for typos and any text errors, for example in the abstract "65y" maybe needs to be changed to "65 years" However, also of note is the section that deals with the subjects from an ethical point of view. The author's state that consent was obtained verbally according to Italian law and that is was not compulsory to submit the study to a normal ethical review board. While the concept and the large nature of this study is very interesting this aspect on ethics maybe should be addressed in a more comprehensive manner. In this regards it should be referred to the editor of the journal and perhaps journal guidelines as normal for a decision in this regards. The author's concept and ideas for this investigation are very note worthwhile and studies of real life experiences are most useful for the field.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 25117

Title: Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

Reviewer's code: 03210617

Reviewer's country: China

Science editor: Xue-Mei Gong

Date sent for review: 2016-02-24 11:32

Date reviewed: 2016-03-27 22:53

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> [Y] Accept
<input type="checkbox"/> [Y] Grade B: Very good	<input type="checkbox"/> [Y] Grade B: Minor language polishing	<input type="checkbox"/> [] The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> [] Grade C: Good	<input type="checkbox"/> [] Grade C: A great deal of language polishing	<input type="checkbox"/> [] Duplicate publication	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> [] Grade D: Fair	<input type="checkbox"/> [] Grade D: Rejected	<input type="checkbox"/> [Y] No	<input type="checkbox"/> [] Minor revision
<input type="checkbox"/> [] Grade E: Poor		BPG Search:	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> [] The same title	
		<input type="checkbox"/> [] Duplicate publication	
		<input type="checkbox"/> [] Plagiarism	
		<input type="checkbox"/> [Y] No	

COMMENTS TO AUTHORS

This study looked at the efficacy and safety of Boceprevir/Telaprevir in combination with Peginterferon/Ribavirin for chronic HCV genotype 1 infection. Several points require further attention: 1.The definitions for "navie", "partial responder", "relapser" and "null responder" should be described in the Methods section,not only in the Table part. 2.According to the previous studies, nonblack race is the predictor of SVR, the race of patients should be analyzed in this study. 3.One important limitation of the study is the heterogenous treatment shedule (Boceprevir or Telaprevir).How many patients received TVR and how many BOC. The author should analyze the subgroup of patients with TVR or BOC in order to provide more generalizable results. 4.The P values should be shown in Results part for fibrosis F1/F2 and F3 stages versus F4 ,IL28B-CC and IL28B-CT versus IL28B-TT, and diabetes at multivariate analysis with logistic regression. 5.More references can be added.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Hepatology

ESPS manuscript NO: 25117

Title: Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience

Reviewer's code: 03021970

Reviewer's country: China

Science editor: Xue-Mei Gong

Date sent for review: 2016-02-24 11:32

Date reviewed: 2016-03-31 10:55

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This Manuscript collected the data coming from several centers in order to check the safety and efficacy of Boceprevir/Telaprevir in combination with Peginterferon/ribavirin in the real-world setting. The results showed that this treatment is safe but with moderate efficacy, especially in certain groups of patients such as those widely represented in our series: advanced fibrosis, non-responder to Peginterferon+ribavirin and over 65y. However, the article need some minor correction before being published. 1.This Manuscript mainly described the safety and efficacy of the direct acting antiviral drugs in HCV infection. So the title of this Manuscript maybe changed to "The safety and efficacy of the Boceprevir or Telaprevir in HCV infection : the Italian real life experience". 2.In this manuscript, the author compared the SVR in different groups divided according to age, but the author should explain why divided all the patients into 3 groups: < 50 ys , 50-65 ys and >65 ys.